博舒替尼治疗经治慢性期慢性髓性白血病患者:4期BYOND研究主要结果
BYOND研究为正在进行的4期研究,纳入163例对既往酪氨酸激酶抑制剂(TKI)耐药/不耐受的CML患者(156例Ph+ CP CML、4例Ph+ AP CML、3例Ph阴性/BCR-ABL1+ CML),接受博舒替尼500 mg每日一次起始剂量治疗。中位治疗时长23.7个月,Ph+ CP CML患者1年累积确认主要细胞遗传学缓解(MCyR)率在既往1或2种TKI后为75.8%、3种TKI后为62.2%,总体1年累积完全细胞遗传学缓解(CCyR)率和主要分子学缓解(MMR)率分别为80.6%和70.5%。
要点
- Ph+ CP CML患者1年累积确认MCyR率:既往1或2种TKI后75.8%,3种TKI后62.2%。
- Ph+ CP CML患者总体1年累积CCyR率80.6%,MMR率70.5%。
- 治疗期间无患者进展至AP/BP;最常见治疗中出现的不良事件为腹泻(87.7%)、恶心(39.9%)和呕吐(32.5%)。
核心结论
- 多数Ph+ CP CML患者在第1年内达到确认的MCyR和MMR,进一步支持博舒替尼用于对既往TKI耐药/不耐受的Ph+ CP CML患者。
研究设计与样本
- 正在进行的4期BYOND研究(NCT02228382),共163例对既往TKI耐药/不耐受的CML患者接受博舒替尼500 mg每日一次起始剂量治疗。
- 患者包括156例Ph+ CP CML、4例Ph+ AP CML和3例Ph阴性/BCR-ABL1+ CML。
- 截至最后入组患者后≥1年,中位治疗持续时间为23.7个月。
主要发现
- Ph+ CP CML患者中,56.4%仍在接受博舒替尼治疗。
- Ph+ CP CML患者1年累积确认MCyR率在既往1或2种TKI后为75.8%,在既往3种TKI后为62.2%。
- Ph+ CP CML患者总体1年累积CCyR率为80.6%,MMR率为70.5%。
- 治疗期间无患者进展至AP/BP。
- 所有患者中最常见的治疗中出现的不良事件为腹泻(87.7%)、恶心(39.9%)和呕吐(32.5%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bosutinib is approved for newly diagnosed Philadelphia chromosome-positive (Ph+) chronic phase (CP) chronic myeloid leukemia (CML) and for Ph+ CP, accelerated (AP), or blast (BP) phase CML after prior treatment with tyrosine kinase inhibitors (TKIs). In the ongoing phase 4 BYOND study (NCT02228382), 163 CML patients resistant/intolerant to prior TKIs (n = 156 Ph+ CP CML, n = 4 Ph+ AP CML, n = 3 Ph-negative/BCR-ABL1+ CML) received bosutinib 500 mg once daily (starting dose). As of ≥1 year after last enrolled patient (median treatment duration 23.7 months), 56.4% of Ph+ CP CML patients remained on bosutinib. Primary endpoint of cumulative confirmed major cytogenetic response (MCyR) rate by 1 year was 75.8% in Ph+ CP CML patients after one or two prior TKIs and 62.2% after three prior TKIs. Cumulative complete cytogenetic response (CCyR) and major molecular response (MMR) rates by 1 year were 80.6% and 70.5%, respectively, in Ph+ CP CML patients overall. No patient progressed to AP/BP on treatment. Across all patients, the most common treatment-emergent adverse events were diarrhea (87.7%), nausea (39.9%), and vomiting (32.5%). The majority of patients had confirmed MCyR by 1 year and MMR by 1 year, further supporting bosutinib use for Ph+ CP CML patients resistant/intolerant to prior TKIs.
引用
- Hochhaus A, Gambacorti-Passerini C, Abboud C, et al. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020. PMID: 32572189. doi:10.1038/s41375-020-0915-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。